Thyrocare Technologies Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Thyrocare Technologies Ltd filed with BSE on 27 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Thyrocare reported consolidated revenue growth of 24.3% and standalone revenue growth of 26.1% in Q1 FY27, with pathology business revenue growing 26% year-on-year. Management highlighted the commercial launch of its Specialty Diagnostics business covering allergy and genomics testing, alongside continued growth in franchisee and partnership channels. The company also discussed a planned divestment of its radiology/nuclear business and updates on franchisee network expansion.
Numbers mentioned
Standalone revenue: INR225.6 crores (Q1 FY27)
p. 8
“Starting with revenue, our stand-alone revenue came in at INR225.6 crores, which is up 26.1% year-on-year, driven by strong growth across the franchisee and pharmacy business.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Consolidated revenue: INR240 crores (Q1 FY27)
p. 8
“On the consolidated business, revenue stood at INR240 crores, reflecting a robust 24.3% year-on-year growth.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Gross margin: 74.1% (Q1 FY27)
p. 8
“Moving to margins and profitability, our gross margins at 74.1%, reflecting an improvement of more than 290 basis points over the year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
EBITDA margin: 32.2% (Q1 FY27)
p. 8
“Our EBITDA margin for the quarter was 32.2%, with EBITDA growing 34% year-on-year.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Profit after tax: INR51.3 crores (Q1 FY27)
p. 8
“Profit after tax stood at INR51.3 crores, with a PAT margin of 21.4%.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Earnings per share: INR3.23 (Q1 FY27)
p. 8
“Earnings per share for the quarter was at INR3.23, compared to INR2.41 crores in the prior period.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Franchisee business growth: 27% (Q1 FY27)
p. 5
“In Q1 FY27, franchisee business delivered 27% Y-o-Y growth.”
Rajdeep Panwar, page 5 of the filed PDF · View the filing
Partnership business growth: 26% (Q1 FY27)
p. 6
“In Q1 FY27, partnership business grew at 26% Y-o-Y.”
Rajdeep Panwar, page 6 of the filed PDF · View the filing
Active franchisees: 11,700 (Q1 FY27)
p. 5
“Our franchisee base has reached its highest level ever at 11,700 active franchisees in Q1 FY27.”
Rajdeep Panwar, page 5 of the filed PDF · View the filing
Radiology PAT: INR1.72 crores (Q1 FY27)
p. 16
“See, first quarter, we did about INR1.72 crores PAT.”
Rahul Guha, page 16 of the filed PDF · View the filing
API Group debt: INR1,050 crores
p. 14
“And as you -- if you have been following, we have been, what you call, selling nonstrategic assets, seeing what all options are there to monetize to bring down the right? I think API will consider an IPO when it is profitable ex-Thyrocare, as well as debt free.”
Rahul Guha, page 14 of the filed PDF · View the filing
ESOP charge: around 3.5 crores (Q1 FY27)
p. 11
“Yes. So ESOPs charge -- so it would be around 3.5 crores in the P&L quarter.”
Vikram Gupta, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Franchisee net additions FY27 — 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4 · FY27
stated firmly by Rahul Guha
p. 20
“No. 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4.”
Rahul Guha, page 20 of the filed PDF · View the filing
Franchisee business growth — mid to high teens · FY27
stated conditionally by Rahul Guha
p. 12
“I will still hold to the mid to high teens guidance at this point in time.”
Rahul Guha, page 12 of the filed PDF · View the filing
Specialty diagnostics share of portfolio — 15% to 20% · three to five year timeline
stated as an aspiration by Rahul Guha
p. 10
“I think our ambition would be to reach the same levels in the three to five year timeline.”
Rahul Guha, page 10 of the filed PDF · View the filing
Radiology business divestment timeline — 6 months
stated conditionally by Rahul Guha
p. 10
“I anticipate the process will take 6 months, right? But we don't have any definitive what you call buyer at this point in time.”
Rahul Guha, page 10 of the filed PDF · View the filing
Radiology PAT for the year — INR6 crores · FY27
stated firmly by Rahul Guha
p. 16
“I think INR6 crores PAT is what we can expect for the year, not more.”
Rahul Guha, page 16 of the filed PDF · View the filing
Consumables business announcement — by September
stated firmly by Rahul Guha
p. 16
“By September, you will see an announcement from us, and I'm sure you will be pleasantly pleased with what we are doing.”
Rahul Guha, page 16 of the filed PDF · View the filing
Specialty diagnostics capex — next year
stated conditionally by Rahul Guha
p. 10
“But I don't anticipate the significant amount of capex going into this business at least next year.”
Rahul Guha, page 10 of the filed PDF · View the filing
API IPO timeline — at least 12 months
stated conditionally by Rahul Guha
p. 14
“I think we are at least 12 months away from both those milestones.”
Rahul Guha, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said it is too early for specific guidance but estimated an ambition to reach peer-level specialty mix over three to five years.
Answered by Rahul Guha
Asked by Abdulkader Puranwala: What is the potential size of the specialty diagnostics portfolio in the next three to four years?
p. 10
“But to just give you an indication, our rough estimate is for most of our peer set, specialty forms between 15% to 20% of that portfolio.”
Rahul Guha, page 10 of the filed PDF · View the filing
Management said the process is expected to take at least 6 months with no definitive buyer yet.
Answered by Rahul Guha
Asked by Abdulkader Puranwala: What is the timeline for divesting the Imaging/nuclear business?
p. 10
“So it's difficult to comment, but I anticipate it will be at least 6 months approval.”
Rahul Guha, page 10 of the filed PDF · View the filing
Management explained calculated parameters not billed to patients were removed from test volume counts for a fairer picture.
Answered by Rahul Guha
Asked by Shubham Harne: Why did the definition of tests conducted change?
p. 11
“So -- but we just felt it's important to restate it so that everyone gets a clear picture.”
Rahul Guha, page 11 of the filed PDF · View the filing
Management indicated the number could be revised and suggested a run-rate of 500-700 per quarter going forward.
Answered by Rajdeep Panwar
Asked by Shubham Harne: Will the yearly franchisee addition target be revised given 900 added in Q1 versus a 1,500 target?
p. 12
“So you can consider 500 to 700 as an average addition every quarter.”
Rajdeep Panwar, page 12 of the filed PDF · View the filing
Management attributed strong growth to base effects and said it was too early to revise full-year guidance.
Answered by Rahul Guha
Asked by Chintan Sheth: Why did franchisee growth outperform the mid-to-high teens guidance this quarter?
p. 12
“Got it. So look, it's too early for me to revise guidance.”
Rahul Guha, page 12 of the filed PDF · View the filing
Management said reports of an API IPO are unfounded and that API is focused on reducing debt and reaching profitability first.
Answered by Rahul Guha
Asked by Sanyam Jain: Are there plans for an API Holdings IPO or reverse merger with Thyrocare?
p. 14
“Yes. You see -- right now, I -- firstly, the news that that floated that API is going for IPO is unfounded.”
Rahul Guha, page 14 of the filed PDF · View the filing
Management said specialty margins should be in line with the current EBITDA margin unless the strategy fails to gain volume.
Answered by Rahul Guha
Asked by Mohammed Patel: Will a 15-20% specialty share dilute overall EBITDA margin?
p. 19
“No. It will actually be more or less in line with our current EBITDA margin.”
Rahul Guha, page 19 of the filed PDF · View the filing
Management said some churn is expected and the 900 figure should be treated as gross, not necessarily a net year-end number.
Answered by Rahul Guha
Asked by Naman Bagrecha: Will the 900 franchisees added in Q1 remain by year end?
p. 20
“So there will be some churn in the -- by the time we reach the end of the year.”
Rahul Guha, page 20 of the filed PDF · View the filing
Risks flagged
Franchisee churn could reduce the net addition figure by year end
p. 20
“So there will be some churn in the -- by the time we reach the end of the year.”
Rahul Guha, page 20 of the filed PDF · View the filing
Core radiology revenue declined due to center consolidation
p. 8
“On a year-on-year basis, core revenue declined by 4%, primarily due to the consolidation of centers.”
Vikram Gupta, page 8 of the filed PDF · View the filing
Specialty diagnostics margins could be diluted if the strategy fails to gain volume
p. 19
“So I don't see them being dilutive unless we fail completely on the strategy and we don't get volume.”
Rahul Guha, page 19 of the filed PDF · View the filing
Nuclear/radiology business has not been growing and has not received continued investment
p. 10
“The nuclear business has not been growing. And we also have not been investing in the nuclear business.”
Rahul Guha, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.